Cybin (CYBN) announced a partnership with closely held Segal Trials to support the multinational pivotal phase 3 program for evaluating CYB003 as a treatment for major depressive disorder.
The phase 3 program plans to enroll 550 patients at more 40 clinical sites in the US and Europe, Cybin said Wednesday in a statement.
Segal Trials, the first program member, has six research sites in South Florida with an emphasis on psychiatry, neurology, addiction and psychedelics, Cybin said.
Shares of Cybin rose 4.8% in recent Wednesday trading.
Price: 9.25, Change: +0.42, Percent Change: +4.78
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。